Hadassah

Hadassah Hosts Israel Heart Society Conference Highlighting Israel’s Cardiac Innovations

Tuesday, Apr 30 2013

With Prof. Chaim Lotan, head of Hadassah's Heart Institute and Outgoing President of the Israel Heart Society (IHS) as host along with IHS Secretary-General Dr. Amit Segev, over 1,000 cardiologists from around the world participated in the IHS's international conference in Jerusalem, celebrating its 60th anniversary and spotlighting Israel's major contributions to the treatment of cardiovascular disease.

Commemorating three of these cardiac contributions, Israel's Philatelic Service recently issued three new postage stamps. One features a percutaneous (inserted through the skin) artificial heart valve; another highlights stents (metal mesh cylinders that release medication and hold open damaged or collapsed coronary arteries); and a third contains an illustration of an implanted defibrillator that electrically regulates a heartbeat. The stamps were unveiled at the IHS conference by Philatelic Service Director Yaron Razon.

Among the leading foreign guests at the conference were American College of Cardiology President Prof. John Harold and European Society of Cardiology President Prof. Panos Vardas. In an interview with The Jerusalem Post, Prof. Harold, a cardiologist at Cedar-Sinai Medical Center in California, related that he has trained many Israeli cardiologists and described the growth of cardiac services in Israel as "nothing short of extraordinary." He also commented: "Israeli cardiologists have great bench-to-bedside developments. Israel is one of the safest parts of the world to have a heart attack."

Prof. Lotan told the audience that the mortality rate from cardiovascular disease has dropped in recent decades by half, and that 90 percent of acute cardiovascular events are treated immediately with catheterization. In addition, he noted that in the last four years, about 1,500 artificial heart valves have been implanted via catheter to replace faulty ones in patients for whom open-heart surgery is counterindicated.

Read more in The Jerusalem Post>>

Comments

No comments yet.
First Name
Email
Comment
Enter this word:

Related Stories

alt_text

Tuesday, Aug 13 2019

Alzheimer’s Further Illuminated at Hadassah with New Exclusive Imaging Agent

The Hadassah Medical Organization, through its subsidiary SRY, has contracted to be the sole Israeli agent for General Electric to produce Vizamy, the company’s new radioactive imaging agent to detect, at an early stage, amyloid plaque, which has been linked to the development of Alzheimer’s disease.

READ MORE ›
alt_text

Friday, Aug 2 2019

New Thyroid Eye Disease Clinic at Hadassah Brings Integrated Care to New Mom

Miriam, 34, had just given birth to her third child, and, unlike the joy she felt after her first two births, she felt awful.

READ MORE ›
alt_text

Friday, Aug 2 2019

Eloxx Pharmaceuticals Announces New Drug Application for Clinical Trial in Cystic Fibrosis Patients

Professor Eitan Kerem, head of the Division of Pediatrics at the Hadassah Medical Organization, will serve as the Global Lead Investigator for this clinical trial.

READ MORE ›
alt_text

Wednesday, Jul 31 2019

Skin Cancer Treatment Enhanced in New Center for Dermatologic Surgery

Thanks to a donation by the Israeli businessman and philanthropist Morris Kahn, a major supporter of the Israeli moon spacecraft “Beresheet,” Hadassah Hospital Ein Kerem has just opened the new Center for Dermatologic Surgery, which offers Mohs surgery for patients with common types of skin cancer.

READ MORE ›
SUPPORT HADASSAH HOSPITALS

Learn more about the Hadassah Medical Organization.

Donation Questions

donorservices@hadassah.org

(800) 928-0685

Membership Questions

membership@hadassah.org

(800) 664-5646

Missions Department

missions@hadassah.org

(800) 237-1517

Contact Us

40 Wall Street

New York, NY 10005

support@hadassah.org

More ›

Show More